首页> Clinical lymphoma, myeloma & leukemia> Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Stephen D,Smith

第一单位： Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: Ssmith50@seattlecca.org.

作者： Stephen D,Smith ^[1] ; Paolo,Lopedote ^[2] ; Yazeed,Samara ^[3] ; Matthew,Mei ^[3] ; Alex F,Herrera ^[3] ; Allison M,Winter ^[4] ; Brian T,Hill ^[4] ; Mazyar,Shadman ^[5] ; Chaitra,Ujjani ^[6] ; Ryan C,Lynch ^[6] ; Caron A,Jacobson ^[7] ; Austin I,Kim ^[7] ; Paolo,Caimi ^[8] ; Filippo,Milano ^[5] ; Ajay K,Gopal ^[6]

作者单位： Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: Ssmith50@seattlecca.org. ^[1] Institute of Hematology, University of Bologna, Bologna, Italy. ^[2] Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA. ^[3] Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH. ^[4] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. ^[5] Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. ^[6] Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA. ^[7] Department of Medicine-Hematology and Oncology, University Hospital/Case Western Reserve Medical Center, Cleveland, OH. ^[8]

关键词 Antibody-drug conjugates Bridging therapy Chemoimmunotherapy Chemorefractory Diffuse large B-cell lymphoma